Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
QIAGEN N.V. develops Sample to Insight technologies for extracting, purifying, amplifying and interpreting DNA, RNA and proteins. Its recurring news covers life sciences and molecular diagnostics applications, including sample technologies, assay technologies, bioinformatics and laboratory automation used in clinical healthcare, pharmaceutical research, academia, forensics and other research settings.
Company updates frequently address product and regulatory developments across QuantiFERON tuberculosis testing, QIAstat-Dx syndromic testing panels, QIAcuity digital PCR, QIAGEN Digital Insights and automated sample-preparation systems such as QIAsymphony and QIAstat-Dx Rise. Financial news also tracks sales trends across consumables, instruments and services, profitability measures, capital-return actions, acquisitions, and changes affecting portfolio growth areas.
QIAGEN has launched QCI Secondary Analysis, a cloud-based software solution that enhances bioinformatics workflows for oncology and inherited disease applications. The software, integrated with QCI Interpret, enables high-throughput secondary analysis of clinical next-generation sequencing data, advancing precision medicine and making NGS testing accessible to smaller labs. The solution provides a secure and compliant environment for bioinformatics workflows, supporting all QIAGEN QIAseq panels.
QIAGEN reported its Q1 2024 results, showcasing net sales of $459 million with a 5% decline, but exceeded expectations with $462 million at constant exchange rates. The company's adjusted operating income margin rose to 25.7% from 25.6% in Q1 2023, with adjusted diluted EPS at $0.46, above the outlook of $0.44. Key growth drivers include double-digit CER growth in QuantiFERON and QIAstat-Dx, resulting in a positive outlook for 2024 with reaffirmed guidance of at least $2.0 billion in net sales and adjusted diluted EPS of at least $2.10 CER.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.